<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><atom:link href="https://www.pccarx.ca/DesktopModules/LiveBlog/API/Syndication/GetRssFeeds?Tag=fda&amp;mid=8604&amp;PortalId=0&amp;tid=999&amp;ItemCount=20" rel="self" type="application/rss+xml" /><title>THE PCCA BLOG</title><description>Stay current on PCCA news and events, market trends, and all things compounding!</description><link>https://www.pccarx.ca/Blog</link><item><title>Advocate for Patients ACT Legislative Conference</title><link>https://www.pccarx.ca/Blog/advocate-for-patients-act-legislative-conference?PostId=385</link><category>General Pharmacy Compounding,Hormone Replacement Therapy,Pharmacy Legislation/Regulation</category><pubDate>Wed, 17 Apr 2024 22:49:16 GMT</pubDate><description>&lt;div class="PCCABlogPost"&gt;&lt;em&gt;&lt;/em&gt;
&lt;p&gt;&lt;em&gt;by Amy Shank, PCCA Director of Government Affairs, and Claire Casey, PCCA Government and Public Affairs Specialist&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;Decision-makers who have met with compounding pharmacists in their districts and those who have toured a compounding pharmacy are more likely to understand the role of compounding in health care. To some, the compounding profession remains misunderstood. Compounders who tell their story — about their patients’ unique medical needs and their role and impact in the community — bridge this education gap.&lt;/p&gt;

&lt;p&gt;The annual ACT Legislative Conference in Washington, D.C., is a key avenue for compounders to connect with their lawmaker and tell their story. Scheduled on May 14-15, 2024, registration remains open for PCCA member compounding pharmacists. Compounders will highlight two front-of-mind concerns.&lt;/p&gt;

&lt;ul class="PCCABlogBullets"&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;strong&gt;Access to Compounded Hormones:&lt;/strong&gt; Patients have relied on compounded hormones for decades when a manufactured product did not meet their medical need. This access is threatened due to recommendations by the National Academies of Sciences, Engineering and Medicine (NASEM)&lt;sup&gt;1&lt;/sup&gt; that state commonly compounded hormones be considered for the FDA’s “difficult-to-compound” products list. If this proposal were fully implemented, patients from all backgrounds would face barriers in accessing therapies that include hormones such as progesterone, testosterone, estradiol and many more. Moreover, it would hinder prescribers and pharmacists from offering suitable treatment options to their patients when commercially available products don’t meet the patients’ needs.&lt;/p&gt;

	&lt;p&gt;A publication in Menopause&lt;sup&gt;2&lt;/sup&gt; shows that there is more evidence available than what was identified and considered by the NASEM committee, and the evidence review process was not thorough — which casts doubt on these recommendations. Prescribers need all available treatment options for their patients.&lt;/p&gt;
	&lt;/li&gt;
	&lt;li&gt;
	&lt;p&gt;&lt;strong&gt;Ensuring the Ability to Provide Informed Feedback to the FDA: &lt;/strong&gt;Following enactment of the Drug Quality and Security Act (DQSA), the FDA has been utilizing guidance documents to enact regulatory framework. From prescription requirements for all human compounds to guidance on insanitary conditions at pharmacies, as well as guidance on medications compounded for animal patients — the FDA has used this guidance process to communicate regulatory directives, including guidelines used during the inspection process. Recently, the agency proposed to issue certain guidance documents “‘for immediate implementation’ without prior public participation.” This effectively eliminates the comment processes from guidance development — and may lead the FDA to implement policies that negatively impact patient safety, access to medical products and overall public health.&lt;/p&gt;

	&lt;p&gt;Pharmacists and pharmacy organizations want an avenue for meaningful dialogue and engagement with the agency, and maintaining an opportunity for a public comment period is critical to this effort. FDA should preserve and enhance its notice and comment process for guidance documents so they are appropriately informed by stakeholder insights and ultimately serve the best interests of public health. PCCA and compounders would like to be a continuing resource for all decision-makers. Our hope is for patient-centric policies that allow continued access to necessary and sometimes lifesaving compounded medications.&lt;/p&gt;
	&lt;/li&gt;
&lt;/ul&gt;

&lt;h3&gt;References&lt;/h3&gt;

&lt;ol class="PCCABlogBullets" style="list-style: auto !important; font-size: 14px;"&gt;
	&lt;li&gt;The National Academies of Sciences, Engineering and Medicine. (2020). The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Accessed April 2024 at &lt;a href="https://nap.nationalacademies.org/resource/25791/cBHT Recommendations Insert.pdf" target="_blank"&gt;https://nap.nationalacademies.org/resource/25791/cBHT%20Recommendations%20Insert.pdf&lt;/a&gt;&lt;/li&gt;
	&lt;li&gt;Liu, Y., Yuan, Y., Day, A.J., Zhang, W., John, P., Ng, D.J., Banov, D. (2022). Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause 29(4); 465-482. Accessed April 2024 at &lt;a href="https://journals.lww.com/menopausejournal/fulltext/2022/04000/safety_and_efficacy_of_compounded_bioidentical.13.aspx" target="_blank"&gt;https://journals.lww.com/menopausejournal/fulltext/2022/04000/safety_and_efficacy_of_compounded_bioidentical.13.aspx&lt;/a&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;/div&gt;

&lt;div id="addName" style="display: none;"&gt;ACT&lt;/div&gt;
</description><guid isPermaLink="false">385</guid></item><item><title>Compounding Update: HCG</title><link>https://www.pccarx.ca/Blog/compounding-update-hcg?PostId=107</link><category>General Pharmacy Compounding,Pharmacy Legislation/Regulation,Testosterone Replacement Therapy</category><pubDate>Wed, 08 Jan 2020 19:07:47 GMT</pubDate><description>&lt;p&gt;&lt;em&gt;By Matt Martin, PharmD, PCCA Clinical Compounding Pharmacist, and Melissa Merrell Rhoads, PharmD, PCCA Director of Formulation Development&lt;/em&gt;&lt;em&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;The FDA has provided a &lt;a href="https://www.fda.gov/media/119229/download" target="_blank"&gt;preliminary list of products&lt;/a&gt; that were originally approved as drug products, but that will be considered biologic products as of March 23, 2020.&lt;sup&gt;1&lt;/sup&gt; Human chorionic gonadotropin, or HCG, is one of these drugs that will now be deemed a biologic product. This means that, starting on March 23, 2020, pharmacies will no longer be able to compound with HCG, and we will be retiring all PCCA formulas that include it at that time.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px;"&gt;Background&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;“Drugs” are generally approved under Section 505 of the Food, Drug, &amp; Cosmetic Act (FD&amp;C Act) while “biologics” generally receive a biologics license under Section 351 of the Public Health Service Act (PHS Act). Traditional pharmacies compounding medications and dispensing them by prescription are considered 503A pharmacies under the FD&amp;C Act. While Section 503A of the FD&amp;C Act provides pharmacies some exemptions, it does not provide an exemption from requiring approval for a biologics license under Section 351 of the PHS Act — meaning that pharmacies cannot compound with biologic products.&lt;sup&gt;2&lt;/sup&gt; You can read more about this framework in the FDA’s guidance document titled &lt;a href="https://www.fda.gov/media/90986/download" target="_blank"&gt;“Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application.”&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px;"&gt;Potential Compounding Options&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;However, compounding is about attempting to solve the needs of patients through innovation in a partnership with the patient and their practitioner. For PCCA members with Clinical Services access, our team of pharmacists are ready to help examine formulations in our database and evaluate if they might be appropriate for patients.&lt;/p&gt;

&lt;p&gt;With that in mind, we have a number of potential compounded formulations for compounders’ consideration if FDA-approved products do not meet the needs of their patients. When HCG had previously been part of a regimen for testosterone therapy, one option for men’s health is the use of &lt;a href="https://www.pccarx.com/Products/ProductCatalog?pid=50-4435" target="_blank"&gt;anastrozole&lt;/a&gt;, as it will help the body continue to make testosterone to minimize the negative-feedback effects of testosterone therapy.&lt;sup&gt;3,4,5&lt;/sup&gt;&lt;/p&gt;

&lt;blockquote&gt;
	&lt;p&gt;PCCA members with Clinical Services access can find a list of &lt;a href="https://www.pccarx.com/Search/Formula?search=12677+11546+10765+10496" target="_blank"&gt;example formulas that include anastrozole and testosterone&lt;/a&gt; in a variety of dosage forms on our Members-Only Website. &lt;/p&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px;"&gt; &lt;/span&gt;&lt;/strong&gt;&lt;em&gt;&lt;a href="https://www.pccarx.com/Blog?cid=39&amp;Category=matt-martin" target="_blank"&gt;Matt Martin&lt;/a&gt;, PharmD, is a Clinical Compounding Pharmacist at PCCA. He joined the PCCA Clinical Services department in September 2014. Matt graduated from Morehead State University with a BS in Chemistry in 2002, and received his PharmD from the University of Kentucky College of Pharmacy in 2006. Prior to joining the PCCA team, Matt worked in compounding pharmacy for more than eight years, and has experience with both sterile and non-sterile preparations.  &lt;/em&gt;&lt;span style="font-size:16px;"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;a href="https://www.pccarx.com/Blog?Category=melissa-merrell-rhoads" target="_blank"&gt;Melissa Merrell Rhoads&lt;/a&gt;, PharmD, PCCA Director of Formulation Development, received her pharmacy degree from Mercer University in Atlanta, Georgia, in 1995. She currently is involved with and oversees the development and implementation of new formulas at PCCA. She had more than six years of compounding experience with pharmacies in Georgia and Florida prior to joining the PCCA staff in 2004. Her areas of interest include women’s health, veterinary and pain management compounding.&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px;"&gt;References&lt;/span&gt;&lt;/strong&gt;&lt;em&gt;&lt;/em&gt;&lt;br /&gt;
	1.    U.S. Food &amp; Drug Administration. (2019). Preliminary list of approved NDAs for biological products that will be deemed to be BLAs on March 23, 2020 [PDF File]. Retrieved from &lt;span style="font-size:11.0pt"&gt;&lt;span style="font-family:"Calibri",sans-serif"&gt;&lt;a href="https://www.fda.gov/media/119229/download" style="color:#0563c1; text-decoration:underline"&gt;https://www.fda.gov/media/119229/download&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
	2.    U.S. Food &amp; Drug Administration. (2018). Mixing, diluting, or repackaging biological products outside the scope of an approved biologics license application: Guidance for industry [PDF File]. Retrieved from &lt;span style="font-size:11.0pt"&gt;&lt;span style="font-family:"Calibri",sans-serif"&gt;&lt;a href="https://www.fda.gov/media/90986/download" style="color:#0563c1; text-decoration:underline"&gt;https://www.fda.gov/media/90986/download&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
	3.    Charnow, J. A. (2013). Anastrozole improves testosterone therapy.&lt;em&gt; Renal &amp; Urology News&lt;/em&gt;. Retrieved from &lt;span style="font-size:11.0pt"&gt;&lt;span style="font-family:"Calibri",sans-serif"&gt;&lt;a href="https://www.renalandurologynews.com/home/departments/mens-health-update/hypogonadism/anastrozole-improves-testosterone-therapy/" style="color:#0563c1; text-decoration:underline"&gt;https://www.renalandurologynews.com/home/departments/mens-health-update/hypogonadism/anastrozole-improves-testosterone-therapy/&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
	4.    DiGiorgio, L., &amp; Sadeghi-Nejad, H. (2016). Off label therapies for testosterone replacement. &lt;em&gt;Translational Andrology and Urology&lt;/em&gt;, 5(6), 588–849. &lt;span style="font-size:11.0pt"&gt;&lt;span style="font-family:"Calibri",sans-serif"&gt;&lt;a href="https://dx.doi.org/10.21037%2Ftau.2016.08.15" style="color:#0563c1; text-decoration:underline"&gt;https://dx.doi.org/10.21037%2Ftau.2016.08.15&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
	5.    National Institute on Aging. (2018). Effects of aromatase inhibition versus testosterone in older men with low testosterone: Randomized-controlled trial. Retrieved from &lt;span style="font-size:11.0pt"&gt;&lt;span style="font-family:"Calibri",sans-serif"&gt;&lt;a href="https://clinicaltrials.gov/ct2/show/NCT00104572" style="color:#0563c1; text-decoration:underline"&gt;https://clinicaltrials.gov/ct2/show/NCT00104572&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;em&gt;&lt;/em&gt;&lt;br /&gt;
	 &lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:11px;"&gt;&lt;em&gt;These statements are provided for educational purposes only. They have not been evaluated by the Food and Drug Administration, and are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
</description><guid isPermaLink="false">107</guid></item><item><title>Working with Compounders: The FDA’s Recent Statement about Oxitriptan</title><link>https://www.pccarx.ca/Blog/compounders-spoke-the-fda-listened-the-agencys-recent-statement-about-oxitriptan?PostId=85</link><category>Pharmacy Legislation/Regulation</category><pubDate>Wed, 28 Aug 2019 17:47:00 GMT</pubDate><description>&lt;p&gt;&lt;em&gt;By PCCA&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;In early May, the FDA made an announcement about oxitriptan, also known as 5-hydroxitryptophan or 5-HTP. It stated that it did “not intend to object to the compounding of oral oxitriptan for patients with BH4 deficiency who have a prescription identifying the disorder, as long as the drug is compounded in compliance with all other conditions of section 503A of the FD&amp;C Act.”&lt;sup&gt;1&lt;/sup&gt; This was a pleasant surprise, since oxitriptan was one of the active ingredients that the FDA had decided not to include on the 503A bulk drug substances list (“the positive list”) according to its final rule that went into effect on March 21 of this year.&lt;sup&gt;2&lt;/sup&gt; &lt;/p&gt;

&lt;p&gt;This is an important statement for patients with BH4 deficiency as well as the practitioners and compounders who help them. Tetrahydrobiopterin (BH4) deficiency is a group of congenital metabolic disorders also known as primary tetrahydrobiopterin (BH4) deficiency, atypical phenylketonuria (PKU) or BH4-deficient hyperphenylalaninemia.&lt;sup&gt;1&lt;/sup&gt; &lt;/p&gt;

&lt;p&gt;In its May announcement about oxitriptan, the FDA stated that several compounding pharmacies and physicians had contacted the agency about compounding with it. One of them was Summit Health Pharmacy in Brookhaven, Pennsylvania, and specifically its owner, Vince Canzanese, RPh (pictured above). Vince had drafted and submitted to the FDA a detailed citizen petition requesting that oxitriptan be added to the positive list and that the agency allow it to be compounded for this patient population in the interim. Vince compounds medications for several patients with BH4 deficiency and works very closely with them as well as their prescribers. In addition to a review of the literature regarding the use of oxitriptan, he also included brief case histories of his patients in the petition.&lt;/p&gt;

&lt;p&gt;While the agency has not added it to the positive list, the FDA announcing that it will not object to oxitriptan being compounded for patients with this condition is an example of the agency taking a patient-centered approach to regulation. Of course, this is also an outstanding example of a compounding pharmacist going out of his way to ensure that his patients have access to the medications they need.&lt;/p&gt;

&lt;p&gt;We applaud the FDA for their decision, and we thank Vince Canzanese along with the other compounders and physicians who contacted the FDA to ensure that patients with BH4 deficiency can continue to receive the compounded medications they need.&lt;/p&gt;

&lt;p&gt;&lt;br /&gt;
	&lt;em&gt;A version of this article originally appeared in PCCA’s members-only magazine, the&lt;/em&gt; &lt;a href="https://www.pccarx.com/Resources/Apothagrams" target="_blank"&gt;Apothagram&lt;/a&gt;. &lt;br /&gt;
	 &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px;"&gt;References&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;
	1.    U.S. Food and Drug Administration. (2019). &lt;em&gt;Communications with stakeholders concerning access to compounded oral oxitriptan for patients with tetrahydrobiopterin deficiency&lt;/em&gt;. Retrieved from &lt;span style="font-size:12.0pt"&gt;&lt;span new="" roman="" style="font-family:" times=""&gt;&lt;a href="https://www.fda.gov/drugs/drug-safety-and-availability/communications-stakeholders-concerning-access-compounded-oral-oxitriptan-patients" style="color:blue; text-decoration:underline"&gt;https://www.fda.gov/drugs/drug-safety-and-availability/communications-stakeholders-concerning-access-compounded-oral-oxitriptan-patients&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
	2.    U.S. Food and Drug Administration. (2019). &lt;em&gt;List of bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act&lt;/em&gt;. Retrieved from &lt;span style="font-size:12.0pt"&gt;&lt;span new="" roman="" style="font-family:" times=""&gt;&lt;a href="https://www.federalregister.gov/documents/2019/02/19/2019-02367/list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in-accordance-with-section" style="color:blue; text-decoration:underline"&gt;https://www.federalregister.gov/documents/2019/02/19/2019-02367/list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in-accordance-with-section&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;/em&gt;&lt;/p&gt;
</description><guid isPermaLink="false">85</guid></item></channel></rss>